DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair,With death on the horizon, This will not stop me, Gods call only..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai) , INDIA 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributio

Tuesday, 12 January 2016

Chris Edlin, Director at Pharmaceutical Manufacturing Technology Centre

Chris Edlin.

Chris Edlin

Director at Pharmaceutical Manufacturing Technology Centre
  • Pharmaceutical Manufacturing Technology Centre
    University of Limerick,
  • Telephone: +353 61 202293
  • Email: chris.edlin@ul.ie




Experienced Research Director, fundraiser and CSO/CEO who has held leadership positions with Sanofi-Aventis, GSK, Roche, Medical Research Council Technology, iThemba Pharmaceuticals and PMTC.

Key Achievements:

• Grew start up from 3 to >25 FTEs
• Established and grew, from grass roots, an international chemistry CRO business with $MM turnover
• Delivered multiple clinical candidates across a variety of therapeutic areas
• Identified, built and funded multiple $MM international projects between Industry, Academia and PPPs

Strong communication, marketing, management and strategic thinking skills. Extensive and robust experience in forming networks and relationships and working across diverse cultures, levels and backgrounds.

Specialties: Production and delivery of business plans, Creating laboratory infrastructure, Hiring senior staff, Board level communication and facilitation, Team building, Innovation optimisation, Synthetic chemistry problem solving, Managing drug discovery and contract research projects, Project Management, Matrix leadership, Stake holder management, Strategy implementation, Neglected disease research, Technology assessment and delivery.

New appointment to lead on partnerships between medical research and industry

Chris Edlin joins as Head of Enterprise Research Partnerships for the College of Medicine, Biological Sciences & Psychology
New appointment to lead on partnerships between medical research and industry
Chris has joined the University of Leicester as Head of Enterprise Research Partnerships for The College of Medicine, Biological Sciences & Psychology, based in the Enterprise and Business Development Office.  He will primarily be responsible for developing new and expanding existing relationships between College research groups and industrial research partners and will take a leading role in assessing the industrial partnership potential of current research strengths across the College and accelerate the development of these enterprise opportunities.
Chris has previously held positions as Chief Scientific Officer at iThemba Pharmaceuticals (Johannesburg, South Africa), Group Leader (Medicinal Chemistry) with the Medical Research Council Technology, Team Leader (Medicinal Chemistry) with GSK and Roche Pharmaceuticals and Senior Medicinal Chemist with Sanofi Aventis.
Chris’s background in drug discovery has given him the opportunity to contribute to a broad range of activities from lead generation to the identification of clinical candidates across a number of different therapeutic areas including inflammation, respiratory diseases, HIV and infectious diseases working directly on multiple different target types (e.g. GPCRs, kinases and enzymes). Furthermore, he has considerable experience in managing drug discovery and contract research projects, matrix leadership, technology assessment and implementation, writing business plans, creating laboratory infrastructure, board level communication, intellectual property assessment and due diligence
He holds a first class degree in Chemistry and a PhD in Organic Chemistry, both awarded by the University of Durham, and is the author of over 40 scientific publications and patents.  He was elected as a Fellow of the Royal Society of Chemistry in 2012.\



Pharmaceutical Manufacturing Technology Centre
 – Present (1 year 11 months)Limerick
Director of a new Centre in Pharmaceutical Manufacturing hosted at the University of Limerick (UL), with an ambitious research and development program. With seed funding from Enterprise Ireland, IDA and an industrial consortium of Irish and multinational companies the Centre will conduct innovative, high quality research in pharmaceutical manufacturing that has direct relevance to industry.

I am responsible for the overall direction, financial control (full P&L) and management of the research in the Centre. I am also responsible for delivering a five-year business plan with defined success metrics and research outcomes that are consistent with this business plan. Critical to the role is taking a leadership role in fostering pharmaceutical manufacturing research at a national and international level, in conjunction with industrial and academic partners, and funding agencies.
The Pharmaceutical Manufacturing Technology Centre (PMTC) is hosted by the University of Limerick with core funding of €1M per annum from the Irish government (Enterprise Ireland and the IDA Ireland). Income is supplemented with co-funding from industry and other public sources.
PMTC, established in December 2013, is led by an industry steering board with an active research program driven by its industry members. Companies access PMTC to create projects and execute world-beating industry-relevant research in advanced technology solutions to address contemporary manufacturing issues.

Head of Enterprise Research Partnerships

University of Leicester
 –  (1 year 2 months)Leicester, United Kingdom

Chief Scientific Officer
iThemba Pharmaceuticals
 –  (3 years 3 months)Johannesburg Area, South Africa
Responsible for project identification and funding in neglected diseases with a primary focus on TB discovery and HIV process innovation. Multiple international collaborative projects initiated and transitioned into H2L and LO. Most senior company officer with full P&L responsibility. Also responsible for fund raising, board and scientific advisory committee communication and company infrastructure and strategy.

Built and grew ($$MM turnover) a contract research division offering H2L and LO chemistry services from South Africa to a range of local and international clients

Director of Chemistry

iThemba Pharmaceuticals
 –  (1 year 4 months)Johannesburg Area, South Africa

Group Leader

 –  (2 years 6 months)London, United Kingdom

Principal Scientist

 –  (4 years)Stevenage, United Kingdom

Team Leader

 –  (1 year)Welwyn Garden City, United Kingdom

Senior Medicinal Chemist

 –  (2 years)London, United Kingdom


University of Limerick

Master of Business Administration (M.B.A.)
 – 2017

Durham University

PhD, Chemistry

Durham University

BSc, Chemistry

First class honours
Awarded ICI scholarship for academic achievement

Honors & Awards

Fellow of the Royal Society of Chemistry

Royal Society of Chemistry

Associated Professor of Chemistry at the University of the Free State

University of the Free State

African Network for Drug Discovery and Diagnostic Innovation Centre of Excellence

World Health Organisation (via ANDI)

UL Hosts New €5M Pharmaceutical Manufacturing Technology Centre

Ul Hosts New €5m Pharmaceutical Manufacturing Technology Centre
The Minister for Skills, Research and Innovation, Damien English TD, recently launched the Pharmaceutical Manufacturing Technology Centre (PMTC) which will be headquartered at the University of Limerick. The State, through the Department of Jobs, Enterprise & Innovation, is investing €5M over the next 5 years in this industry-focussed Centre which will deliver advanced technology solutions to contemporary manufacturing issues currently challenging the Irish pharmaceutical sector. PMTC is the latest of 15 state-supported Technology Centres established jointly by Enterprise Ireland and IDA Ireland. The Centre brings together 24 industry partners and 9 Higher Education Institutes who will deliver the research.

The aim of PMTC is to make Ireland the global hub of pharmaceutical process innovation and manufacturing and ultimately support an industry which directly employs over 25,000 people. Manufacturing cost competitiveness and patent expiry are among the two most critical issues which threaten the future of this industry which contributes over €40BN in Irish exports per annum. The industry consortium currently comprises a mix of indigenous multinational pharmaceutical companies and SME’s including: Alkermes, Allergan Pharmaceutical, Applied Process Consulting, Astellas, Bristol-Myers Squibb Swords, Crest Solutions, Eli Lilly, Gilead, GSK, Helsinn Birex, Innopharma Labs, Janssen, Label Art, Leo Pharma, Merck Sharp Dohme, Pfizer, Process Analytics, Roche, Servier, Sigmoid Pharma, Takeda Pharmaceuticals, Techno-Path, Teva Pharmaceuticals and TopChem Pharma.
Pictured above are: Dr Chris Edlin, Director, PMTC, Minister Damien English, Dr Mary Shire, Vice President Research, UL, Professor Gavin Walker, Bernal Chair of Pharmaceutical Powder Engineering, UL and PMTC Research Team

Emma R Parmee, Associate Vice President, Head of Exploratory Chemistry at Merck

Emma R Parmee

Emma R Parmee

Associate Vice President, Head of Exploratory Chemistry at Merck


Emma Parmee is an Associate Vice President leading the Exploratory Chemistry Group at Merck and Co.. In that capacity she is responsible for a cross-network group whose role is to identify and advance novel projects to the Lead Optimization stage gate. Previously, she was head of the Discovery Chemistry Department at Merck & Co.'s West Point, PA. Until 2010 she was in the Medicinal Chemistry department at Merck & Co., Rahway, NJ., where she rose to the level of Senior Director, working in Cardiometabolic Diseases. She obtained her Bachelor's and Doctoral degrees in Organic Chemistry from Oxford University in the U.K. She then came to the U.S. and held a NATO Postdoctoral position at MIT where her work focused on the development of novel catalytic asymmetric aldol reactions. Emma has over twenty years of experience in the Pharmaceutical industry working in numerous therapeutic areas.

Emma Parmee is a British chemist and research scientist who is a co-inventor of numerous drug patents. She was one of the leading researchers in the development of sitagliptin and was awarded a Thomas Alva Edison Patent Award in 2007 and the Society of Chemical Industry's Gordon E Moore Medal in 2009 for her contributions.

Invited Keynote Industry Speaker Dr. Emma R. Parmee......Boston WInCS 2014

Emma Parmee
Emma Parmee Medal Dinner 2009 detail.jpg
Emma Parmee at the award of the 2009 Gordon E Moore Medal
Other namesEmma Rachel Parmee
Alma materUniversity of Oxford
Massachusetts Institute of Technology
EmployerMerck & Co.


Associate Vice President, Head of Exploratory Chemistry

 – Present (2 years 3 months)Weat Point, PA

Executive Director, Discovery Chemistry Site Head - WP

 –  (2 years 1 month)

Senior Director

 –  (18 years)


University of Oxford

BA/PhD, Organic Chemistry